GE HealthCare Technologies Inc. $GEHC Stock Acquired by ProShare Advisors LLC

Key Points

• ProShare Advisors increased its GE HealthCare stake by 2.8% in the third quarter, bringing its holdings to 518,028 shares worth approximately $33.9 million. Institutional investors collectively own 82.06% of GEHC.
• GE HealthCare delivered stronger-than-expected third-quarter results, with revenue up 7.2% year over year to $5.51 billion and EPS of $1.34 versus the $1.20 consensus estimate. Management raised its full-year outlook for organic growth, adjusted EPS and free cash flow.
• Analyst sentiment remains positive overall: several firms raised their price targets, and GEHC has a “Moderate Buy” consensus rating with an average target of $80.57. The company also increased its quarterly dividend to $0.04 per share.

ProShare Advisors LLC boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 2.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 518,028 shares of the company's stock after purchasing an additional 14,052 shares during the quarter. ProShare Advisors LLC owned about 0.11% of GE HealthCare Technologies worth $33,863,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of GEHC. State Street Corp raised its stake in GE HealthCare Technologies by 1.6% during the second quarter. State Street Corp now owns 20,861,566 shares of the company's stock worth $1,335,349,000 after purchasing an additional 323,090 shares during the period. Barrow Hanley Mewhinney & Strauss LLC grew its stake in shares of GE HealthCare Technologies by 13.2% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 13,455,814 shares of the company's stock valued at $861,307,000 after buying an additional 1,571,226 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of GE HealthCare Technologies by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,399,439 shares of the company's stock valued at $384,219,000 after buying an additional 105,995 shares during the period. Van ECK Associates Corp increased its holdings in shares of GE HealthCare Technologies by 4.1% during the 2nd quarter. Van ECK Associates Corp now owns 4,482,631 shares of the company's stock worth $286,933,000 after buying an additional 177,028 shares during the last quarter. Finally, Trian Fund Management L.P. increased its holdings in shares of GE HealthCare Technologies by 76,194.4% during the 2nd quarter. Trian Fund Management L.P. now owns 3,085,344 shares of the company's stock worth $197,493,000 after buying an additional 3,081,300 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Key Stories Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Strong Q3 results beat expectations. GE HealthCare reported $5.51 billion in revenue, above the $5.35 billion consensus estimate, while EPS of $1.34 exceeded expectations of $1.20. Revenue increased 7.2% year over year, helping drive the post-earnings gap higher. GE HealthCare Technologies Shares Gap Up After Strong Earnings
• Positive Sentiment: Management raised its full-year outlook. The company now expects approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and at least $1.6 billion in free cash flow. Organic growth of 6.2% and margin expansion in the quarter further strengthened the bullish case. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Analysts raised valuation targets. RBC increased its target from $80 to $90 and maintained an “outperform” rating. BNP Paribas lifted its target from $96 to $100, while Mizuho raised its target from $85 to $90. BTIG Research also forecast substantial potential appreciation. BNP Paribas Price Target Update
• Neutral Sentiment: JPMorgan raised its price target from $70 to $80 but kept a “neutral” rating, suggesting recognition of the earnings improvement while retaining a cautious stance on valuation. JPMorgan GE HealthCare Rating
• Neutral Sentiment: A value comparison with Haemonetics highlights GEHC’s investment appeal but does not introduce a material new catalyst for the stock. GEHC Versus HAE Value Comparison

Analysts Set New Price Targets

A number of research analysts recently weighed in on GEHC shares. Piper Sandler reiterated a "buy" rating on shares of GE HealthCare Technologies in a report on Wednesday, July 29th. Needham & Company LLC reissued a "buy" rating and set a $93.00 price target on shares of GE HealthCare Technologies in a research report on Monday, October 5th. Weiss Ratings upgraded GE HealthCare Technologies from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, October 6th. Hovde Group began coverage on GE HealthCare Technologies in a report on Friday, July 17th. They issued a "market perform" rating and a $14.00 price objective on the stock. Finally, Wall Street Zen upgraded GE HealthCare Technologies from a "hold" rating to a "buy" rating in a report on Saturday. Twelve investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of "Moderate Buy" and a consensus target price of $80.57.

GE HealthCare Technologies Price Performance

GEHC opened at $76.57 on Monday. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a 50 day moving average of $68.45 and a two-hundred day moving average of $70.06. The company has a market cap of $34.62 billion, a P/E ratio of 16.15, a P/E/G ratio of 1.93 and a beta of 0.64. The company has a quick ratio of 1.01, a current ratio of 1.30 and a debt-to-equity ratio of 0.86.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.14. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.35 billion. GE HealthCare Technologies had a net margin of 9.96% and a return on equity of 20.45%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.07 EPS. On average, analysts expect that GE HealthCare Technologies Inc. will post 5.02 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.04 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.16 annualized dividend and a yield of 0.2%. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.0350. GE HealthCare Technologies's payout ratio is currently 3.38%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company's portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.